Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy

Executive Summary

CSL’s Hemgenix is the latest expensive gene therapy to come under scrutiny from the BeNeLuxA cross-country coalition.

You may also be interested in...



England: CSL Undeterred By Draft NICE Rejection Of Its £2.6m Hemophilia B Gene Therapy

CSL Behring said it remains confident that a market access agreement for its hemophilia B gene therapy Hemgenix can be reached after England’s HTA body NICE rejected the product because of uncertainties over its long-term benefit and cost-effectiveness.

Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks

The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.

Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut

Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel